#pharmaceuticals

Drugmakers seeking a reduced 20% tariff rate will face extensive paperwork and close monitoring by the Department of Commerce under a new executive order.

Varda Space Industries has signed a collaboration with United Therapeutics to explore whether microgravity can improve the stability and delivery of treatments for rare lung disease.

Pfizer chief executive Albert Bourla said “no” when asked whether the company would pursue a transformative merger or acquisition in the near or medium term, signaling a restrained stance on large-scale dealmaking.

Novartis chief executive Vas Narasimhan says the company is very disappointed by Germany’s plan to cut more than €60 billion in healthcare costs, setting up an early clash over the consequences for drug sales and market

Amgen says longtime executive David Reese, who currently serves as chief technology officer, will retire at the end of June, marking a leadership change inside one of biotech’s largest companies.

Amneal Pharmaceuticals has agreed to acquire a biosimilar maker for $375 million upfront, highlighting how manufacturers are still using targeted deals to widen portfolios and strengthen their position in harder-to-proc

Anthropic’s appointment of Novartis CEO Vas Narasimhan to its board points to a closer alignment between frontier AI development and the pharmaceutical industry.

A newly approved daily weight-loss pill moved through U.S. FDA review faster than most drugs in recent years, signaling continued momentum in the obesity treatment market.

Eli Lilly and Insilico Medicine have signed a deal worth up to $2.75 billion, deepening a partnership aimed at moving AI-developed drug candidates toward the global market.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Vinay Prasad, a controversial figure at the FDA's biologics center and key ally of Commissioner Makary, is leaving the agency.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.